Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in.
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
Dec. 31 Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. has been awarded orphan drug status by the US Food and Drug Administration for its PLX-PAD cells treatment for severe preeclampsia. We are encouraged by the US FDA designation that demonstrates Pluristem's commitment to the program and the potential promise it holds
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
By a News Reporter-Staff News Editor at Politics& Government Week Since 2006, the number of industry-sponsored clinical trials studying the benefits and harms of medical treatments has risen dramatically, while the number of clinical trials funded by the National Institutes of Health has fallen substantially, according to new Johns Hopkins Bloomb
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
The Report Deep Brain Stimulators- Medical Devices Pipeline Assessment, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Deep Brain Stimulators- Medical Devices Pipeline Assessme
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
Tenders are invited for Rfa Fibre For Bipolar Intraluminal Application For Varicose Veins Detail Specification: Us Fda/ European Ce Approved Quality. Instructions/Remarks: All The Firms Participating In E-Tender Enquiry To Upload The Details Of The Offered Item In The Form Of Scanned Copy Of The Photo Of The Offered Item Showing All Relevant Detail
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration has granted the Company s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies o
Aurobindo declared that the Food and Drug Administration approved its famotidine tablets in the 20 mg and 40 mg strengths to treat gastroesophageal reflux diesease and active duodenal ulcer. The permitted ANDA is bioequivalent and therapeutically equivalent to Pepcid tablets, 20 mg and 40 mg, from Valeant Pharmaceuticals. Famotidine tablets have an
Alnylam Pharmaceuticals has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. According to a release, the initiation of this trial has triggered a $10 million milestone from The Medicines Company to Alnylam. Together with The Medicines Company, we look forward to the continued...
Alnylam Pharmaceuticals has initiated the Endeavour Phase 3 clinical trial of revusiran in transthyretin- mediated familial amyloidotic cardiomyopathy. Alnylam is eligible to receive a $25 million milestone from Genzyme when the first patient is dosed in the Endeavour study. Initiation of Endeavour highlights our continued execution on our product.
ARCA Biopharma has activated the first Genetic-AF clinical trial site in Canada. ARCA plans to activate a total of approximately 60 clinical trial sites in the United States and Canada for the Phase 2 B portion of the trial. Stuart Connolly, MD, Director of the Division of Cardiology at McMaster University in Hamilton, Ontario, Canada, and Co-Chair
WASHINGTON- Aquinox Pharmaceuticals Inc. has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis. ARIAD Pharmaceuticals Inc. has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries. The seven countries include Bulgaria, the Czech
By a News Reporter-Staff News Editor at Biotech Week BioTime, Inc. announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development
By a News Reporter-Staff News Editor at Biotech Week CSL Behring announced it has submitted a biologics license application to the United States Food and Drug Administration for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin. Once approved by the FDA, rIX-FP will pr